Fecal Elastase Test: What It Is and What Low Levels Mean

The fecal elastase test measures the concentration of elastase-1, a digestive enzyme made by the pancreas, in a stool sample. When levels come back low, it signals that the pancreas is not producing enough enzymes to properly break down food, a condition called exocrine pancreatic insufficiency (EPI). The test is straightforward, non-invasive, and widely used, but interpreting the results involves more nuance than a single number might suggest.

What Elastase-1 Is and Why It Makes a Good Marker

Elastase-1 is one of several enzymes the pancreas secretes to help digest food, particularly proteins. What makes it useful as a diagnostic marker is its durability: unlike most pancreatic enzymes, elastase-1 survives the entire journey through the gastrointestinal tract without being significantly broken down. By the time it reaches the stool, it has actually become more concentrated, roughly five- to six-fold compared to its levels in pancreatic juice.¹ That stability and natural enrichment mean the amount in your stool reliably reflects how much your pancreas is actually producing.

The test itself uses a laboratory method called an ELISA (enzyme-linked immunosorbent assay) built around antibodies that specifically recognize human elastase-1.² That specificity matters for a practical reason: if you are already taking pancreatic enzyme replacement supplements (which are derived from pigs), the test will not pick up the animal enzymes and confuse them with your own. You do not need to stop supplements before collecting a sample.

What the Numbers Mean

Results are reported in micrograms of elastase-1 per gram of stool. The standard interpretation breaks down into three bands:

Above 200 µg/g: Normal pancreatic function.
100–200 µg/g: Mild to moderate pancreatic insufficiency.
Below 100 µg/g: Severe pancreatic insufficiency.

That 200 µg/g cutoff is the one most clinicians rely on. In one of the foundational studies validating the test, using this threshold gave a sensitivity of 100% for moderate and severe insufficiency and 93% overall across all grades. Specificity was also 93%, meaning few people without pancreatic problems get a falsely low result.³ Where the test struggles is with mild disease: sensitivity dropped to 63% for patients with only mild insufficiency. So a normal result does not completely rule out early-stage problems.

How Accurate Is the Test, Really?

A large systematic review pooling data from 14 studies and over 1,100 patients compared fecal elastase-1 against the secretin stimulation test, which is the older, more invasive gold standard. The pooled sensitivity was about 77% and specificity about 88%.⁴ Those numbers are decent but not perfect, and they highlight an important point: how useful the test is depends heavily on the likelihood you had pancreatic insufficiency in the first place.

In someone with a low chance of EPI (say, around 5%), the test is excellent at ruling the condition out. The false-negative rate in that scenario is only about 1%. But the false-positive rate climbs to around 11%, meaning you could get a low result even though your pancreas is fine.⁴ In someone with a high probability of EPI (around 40%), roughly 10% of true cases would be missed. The takeaway is that the test works best when paired with clinical judgment, not used as a standalone screening tool on anyone with vague digestive complaints.

The Pancreatic Conditions That Drive Low Levels

When fecal elastase comes back low, the most common pancreatic culprits fall into a few categories.

Chronic pancreatitis is the classic one. Long-standing inflammation gradually destroys the enzyme-producing tissue of the pancreas, steadily reducing its output.⁵ Alcohol-related damage is the most recognized cause of chronic pancreatitis, but autoimmune pancreatitis, hereditary forms, and idiopathic cases (where no clear cause is found) can do the same thing. The enzyme decline tends to be progressive: early chronic pancreatitis may produce borderline results on fecal elastase, while advanced disease drives levels well below 100 µg/g.

Cystic fibrosis often causes severe pancreatic insufficiency from a young age. In one study, every patient who carried two copies of the most common cystic fibrosis mutation had undetectable elastase-1 in their stool, and the degree of insufficiency tracked with the specific genetic mutations involved.⁶ Most people with cystic fibrosis are diagnosed in childhood, but milder mutations occasionally escape detection until adulthood, when persistent digestive trouble prompts testing.

Pancreatic tumors can obstruct the pancreatic duct, leading to a buildup of pressure that damages the gland behind the blockage. Over time this causes fibrosis and destruction of healthy tissue, much like chronic pancreatitis does.⁷ A low fecal elastase result is not used to diagnose cancer on its own, but it can help guide nutritional support in people who already have a known pancreatic mass.

Pancreatic surgery is another major driver. Removing part of the pancreas, as in a Whipple procedure (pancreaticoduodenectomy) or distal pancreatectomy, physically reduces the amount of tissue available to produce enzymes. More than two-thirds of studies report that over 65% of patients who undergo these operations develop EPI afterward.⁸ The insufficiency can worsen over the first year: one study found reduced elastase levels in about half of patients at three months, climbing to nearly three-quarters at one year post-surgery, before settling back to around half at two years.⁹

Low Elastase Without Primary Pancreatic Disease

A result that surprises many people: you can get a low fecal elastase reading even if your pancreas is structurally normal. This is where interpretation gets tricky.

Diabetes is a well-recognized association. The pancreas produces both digestive enzymes (exocrine function) and hormones like insulin (endocrine function) in different cell types that sit close together. Insulin has a growth-promoting effect on the enzyme-producing cells, so when insulin production drops or when insulin resistance reduces its local impact, the exocrine tissue can shrink.¹⁰ This means both type 1 and type 2 diabetes can lead to genuine low elastase levels, not as a false positive, but as real (though sometimes mild) insufficiency that many clinicians underappreciate.

Celiac disease is another condition linked to low fecal elastase. Among celiac patients with chronic diarrhea, about 30% had low elastase readings in one study, compared to only 4% in healthy controls.¹¹ The mechanisms are debated. Some researchers think the inflamed small intestine in celiac disease disrupts the hormonal signals that tell the pancreas to secrete enzymes, while others suspect the finding represents a secondary pancreatic insufficiency. Either way, clinicians who see persistent diarrhea in a celiac patient despite a gluten-free diet should consider checking fecal elastase.

Pitfalls That Can Skew Results

The test measures concentration, not total output. That distinction matters because anything that dilutes the stool can artificially lower the result. Watery or very loose stools, such as those caused by an acute bout of gastroenteritis or osmotic diarrhea, dilute the elastase present and may produce a falsely low reading.¹² For this reason, most labs recommend collecting a formed stool sample when possible. If you can only produce a loose sample, flagging this for your doctor is important so the result can be interpreted cautiously.

On the other hand, enzyme replacement supplements do not interfere with the test, since the ELISA uses antibodies that only recognize the human version of elastase-1. This is a genuine advantage over older pancreatic function tests, which could be thrown off by exogenous enzymes.

A single low result in someone without obvious symptoms or risk factors should prompt a repeat test rather than immediate alarm. Random day-to-day variation, sample handling issues, and the dilution effect mentioned above can all produce one-off low readings that do not reflect true insufficiency.

What Happens in Your Body When Elastase Is Chronically Low

When the pancreas does not produce enough digestive enzymes over weeks and months, the consequences go well beyond loose stools. The most direct problem is fat malabsorption: without adequate lipase (another pancreatic enzyme whose decline parallels elastase’s), dietary fat passes through undigested. This produces the greasy, foul-smelling stools (steatorrhea) that many patients with EPI recognize.¹³

Fat malabsorption also means you cannot properly absorb the fat-soluble vitamins A, D, E, and K. Over time, this leads to deficiencies that can affect bone health (vitamin D), vision and immune function (vitamin A), neurological function (vitamin E), and blood clotting (vitamin K). These deficiencies can develop quietly, sometimes before digestive symptoms become severe enough to prompt investigation.¹⁴ Weight loss and general malnutrition are common in untreated EPI, and in children, poor growth and failure to thrive can be the first red flag.

Treatment After a Confirmed Low Result

The mainstay of treatment is pancreatic enzyme replacement therapy, or PERT. These are capsules containing a mixture of lipase, protease, and amylase derived from pig pancreas, taken with meals and snacks to replace the enzymes your pancreas is not producing. A systematic review of PERT in chronic pancreatitis found that it significantly improved fat absorption compared to both baseline and placebo, while also reducing stool fat, stool weight, and abdominal pain without causing major side effects.¹⁵ Follow-up data from the same review showed improvements in blood nutritional markers, gastrointestinal symptoms, and quality of life.¹⁶

Dosing PERT is not one-size-fits-all. The amount of lipase units needed per meal depends on the severity of insufficiency, the fat content of the meal, and individual response. Clinicians typically start with a standard dose and adjust based on symptom improvement and, sometimes, follow-up stool tests.

Beyond enzymes, nutritional monitoring is an essential part of managing EPI. Fat-soluble vitamin levels should be checked regularly, and supplementation started when deficiencies are found. In a study of cystic fibrosis patients, providing appropriate doses of vitamins A, D, and E alongside enzyme therapy was enough to normalize vitamin profiles despite ongoing malabsorption.¹⁷ In children with EPI, a high-energy diet with unrestricted fat intake (paired with adequate enzyme dosing) is often recommended to support growth and prevent nutritional deficits.¹⁸ The older advice to restrict fat has largely fallen out of favor, since the goal of enzyme therapy is to allow normal fat digestion, not to avoid fat altogether.

Age at Both Ends of the Spectrum

Newborns, particularly premature infants, naturally have low fecal elastase levels that should not be confused with disease. In a study of premature and full-term infants, the first stool sample (meconium) showed levels well below the 200 µg/g threshold in every baby regardless of gestational age, averaging around 46 µg/g. By the second sample, levels had climbed to a mean of about 243 µg/g, but the more premature the baby, the longer it took for elastase to reach normal.¹⁹ Pediatricians screening for cystic fibrosis or other congenital conditions need to account for this maturation period rather than assuming low neonatal levels are pathological.

At the other end of life, pancreatic function appears to decline with age even in the absence of obvious disease. A study of older adults without known gastrointestinal conditions or diabetes found that elastase levels correlated negatively with age, with significantly lower values in people over 70. Among those over 60, roughly 22% fell below the 200 µg/g cutoff, with a mean of about 112 µg/g in that subgroup.¹ Whether all of these individuals actually have clinically meaningful malabsorption, or whether the cutoff simply does not apply the same way to older adults, remains an open question. But it means a borderline-low result in someone over 70 warrants more context before jumping to a diagnosis.

Using Fecal Elastase Alongside Other Stool Markers

Doctors sometimes pair fecal elastase with other stool tests to narrow down what is going on, particularly when the clinical picture is muddy. One interesting pairing is fecal calprotectin, a marker of intestinal inflammation commonly used to evaluate inflammatory bowel disease. Research has found that low fecal elastase was independently associated with elevated fecal calprotectin in patients with pancreatic diseases, suggesting that pancreatic insufficiency itself can trigger intestinal inflammation, probably because undigested food irritates the gut lining.²⁰ This means a high calprotectin result does not automatically point to Crohn’s disease or ulcerative colitis; untreated EPI can mimic that inflammatory signal.

This overlap matters in practice. Someone with chronic diarrhea, weight loss, and an elevated calprotectin might be sent down an inflammatory bowel disease workup with colonoscopies and imaging. Checking fecal elastase early in that process can sometimes redirect the investigation toward the pancreas, potentially saving time and unnecessary procedures. The two tests cost relatively little and require only a stool sample each, making the combination practical even as a first-pass screen.

When a Low Result Is Not What It Seems

The fecal elastase test is a snapshot of enzyme concentration, not a direct look at pancreatic structure. A confirmed low result does not tell you why the pancreas is underperforming. Imaging, usually with CT or MRI of the abdomen, is typically the next step to look for structural causes like chronic pancreatitis, tumors, or duct obstructions. In some cases, endoscopic ultrasound provides a more detailed view of subtle changes in the pancreatic tissue.

There are also situations where a low result is real but self-limited. Acute pancreatitis, for instance, can temporarily suppress enzyme output while the gland is inflamed. Levels often recover as the acute episode resolves, so testing during or immediately after an attack may not reflect your long-term pancreatic function. Similarly, small bowel bacterial overgrowth and other conditions that speed up intestinal transit can produce diluted stools and borderline-low readings without true pancreatic pathology. The pattern to watch for is persistently low results on repeat testing, ideally on formed stool samples collected at different times.